essence trial semaglutide In an interim analysis of a phase 3 involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly improved liver histologic results at 72 weeks. Full trial results and Research Summary Semaglutide Improves Histology in MASH:

16 Trial design This was a single-center, randomized, placebo-controlled, double-blind, two-period incomplete crossover trial

Assessment of risk of bias The SYRCLE tool was applied to estimate the risk of bias from individual studies [25]

First 2 weeks: reduced inflammation, improved mobility in acute injuries Weeks 34: measurable reduction in pain

Identifying relevant studies for systematic reviews

Compounded peptides are sometimes offered when branded medications are expensive or in short supply, but the FDA has warned that compounded semaglutide and tirzepatide may not meet the same safety or quality standards as FDA-approved products (FDA statement on compounded semaglutide)